Axitinib

Axitinib (CAS 319460-85-0) is a pharmaceutical-grade active ingredient manufactured directly by the supplier to USP and Ph. Int standards. It is a second-generation tyrosine kinase inhibitor that selectively blocks VEGFR-1, -2 and -3, used for advanced renal cell carcinoma after failure of a first-line systemic treatment, and is distributed across Western and Eastern Europe, Asia and the Middle East.